Mucin and other extracellular glycoproteins

Mucins and other extracellular glycoproteins are a diverse class of high-molecular-weight proteins characterized by extensive O-linked and N-linked glycosylation. They are primarily produced by epithelial cells and are essential components of the extracellular matrix and mucus layers, providing lubrication, hydration, and a physical barrier against pathogens (PubMed: 15549398). In various diseases, particularly adenocarcinomas, mucins like MUC1 and MUC16 are frequently overexpressed or aberrantly glycosylated, contributing to tumor cell survival, metastasis, and immune evasion (PubMed: 25135138). These proteins also play a role in chronic inflammatory conditions of the respiratory and gastrointestinal tracts, where altered expression leads to impaired clearance and obstruction. Therapeutic strategies include the use of mucolytic agents like N-acetylcysteine, which reduce mucus viscosity by cleaving disulfide bonds between mucin monomers (PubChem: CID 12035). Additionally, monoclonal antibodies such as Oregovomab and Gatipotuzumab are designed to target specific tumor-associated mucin epitopes for cancer immunotherapy (UniProt: P15941, Q8WXI7). While they serve as critical biomarkers for disease progression, targeting these proteins requires precision to avoid disrupting the protective functions of normal mucosal surfaces. Overall, this class of glycoproteins represents a complex set of targets involved in maintaining tissue homeostasis and driving pathological progression in cancer and inflammation.

Other names

MucoproteinsMucus glycoproteinsExtracellular matrix glycoproteinsEpithelial mucinsProteoglycans

Mucolytic agents reduce mucus viscosity by cleaving disulfide bonds in mucin polymers; monoclonal antibodies target specific mucin epitopes to induce antibody-dependent cellular cytotoxicity (ADCC) or inhibit oncogenic signaling.